32 results about "Corilagin" patented technology

The invention discloses an application of various compounds such as polyphenols in resisting coronavirus. The invention relates to the application of one or more of a polyphenol substance, a proton pump inhibitor, p-benzoquinone and a derivative thereof, an active ingredient of sappan wood, TDZD-8, thiomersalate, alkannin, Tidelusib, protoflavin, rabeprazole sodium, PX-12, Dixanthophygen, methyl cholate, carbamofluorine, corilagin, dihydromyricetin, chloramine T, merbromin, gallocatechin, fraxetin, meisoindigo, a lactic acid ethacridine monohydrate and sousoprazole in preparation of drugs for treating and/or preventing diseases caused by coronavirus. In-vitro enzyme activity experiments show that various compounds such as 1, 4-naphthoquinone and the like can well inhibit the activity of main protease in the coronavirus, and the defect that diseases caused by the coronavirus cannot be treated in the prior art is overcome.

The invention discloses an extraction-separation method and an application of corilagin. The method comprises the steps of treating longan kernel powder once by using anhydrous acetone and extracting by using acetone aqueous solution again for the second time; uniformly mixing a proper amount of chromatography polyamide with the acetone aqueous solution, recycling acetone and applying to a polyamide chromatography column; eluting by sequentially using pure water, methyl alcohol aqueous solutions with different concentrations and methyl alcohol; gathering 40-60 percent of methyl alcohol eluant in a separate bottle form, condensing and separating out corilagin crystals; mixing mother liquid with the rest of eluant containing corilagin, condensing to be dry, dissolving into methyl alcohol and applying to a polydextran gel LH-20 column; eluting by methyl alcohol; gathering eluant in a separate bottle form and standing; mixing with the eluants in which corilagin crystals are separated out; standing again until the orilagin crystals which are separated out are not increased; mixing the obtained corilagin crystals with corilagin crystals obtained by chromatography polyamide; performing recrystallization by using ethyl alcohol to obtain corilagin with high purity. The corilagin subjected to extraction and separation has a function of inhibiting tyrosinase.

The invention belongs to the technical field of plant extraction, and particularly relates to an emblic leafflower fruit extract capable of dispelling the effects of alcohol and protecting the liver as well as a preparation method and application thereof. The preparation method comprises the following steps: cleaning fresh emblic leafflower fruits, denucleating and drying the fresh emblic leafflower fruits, crushing the fresh emblic leafflower fruits, carrying out sieving to obtain emblic leafflower fruit micro-powder, adding water, carrying out extracting at 70-90 DEG C for 8-15 minutes, carrying out centrifuging to obtain an emblic leafflower fruit extracting solution, further concentrating the emblic leafflower fruit extracting solution, and adding water for re-dissolving; adding ethylacetate for extraction, and collecting an extraction phase; and further concentrating the extract phase to obtain the emblic leafflower fruit extract capable of dispelling the effects of alcohol and protecting the liver. The main components of the extract are gallic acid, corilagin and ellagic acid, wherein the content of gallic acid is the highest and reaches 2.42mg/g, gallic acid has a good inhibition effect on BRL-3A alcoholic injury, that is, gallic acid has a good protection effect on BRL-3A cells with alcoholic injury, and the damage of alcohol to the liver is further reduced by increasing the SOD content and reducing the MDA content, the ALT content and the AST content.

The invention relates to a Corilagin compound, in particular to the application of Corilagin in preparing anti-tumor drugs. The chemical name of Corilagin is 1-O-trigalloyl-3,6-O-hexahydroxydiphenoyl-beta-D-glucose, and the molecular formula thereof is C27H22O18. The anti-tumor drug for oral administration or injection comprises a drug resisting the tumor growth or a drug resisting tumor invasionand metastasis, wherein the injection can be intravenous injection, intramuscular injection, intraperitoneal injection or subcutaneous injection. According to the tests, the Corilagin achieves good anti-tumor effect, more particularly, the Corilagin achieves good curative effect in both in-vitro tumor cell tests and in-vivo tumor animal models. Therefore, the Corilagin as a novel compound achieving the anti-tumor effect is applicable in preparing anti-tumor drugs.

The invention relates to a construction method and application of a medicine Terminalia fruit and Terminalia chebula Retz.var.tomentella Kurt. medicinal material characteristic spectrum. The construction method of the medicine Terminalia fruit medicinal material specific chromatogram comprises the following steps: preparing a reference substance solution by taking gallic acid, ethyl gallate, corilagin, Chebulagic acid, myrobalan acid and chebulic acid as reference substances; dissolving a medicine Terminalia fruit in a solvent, performing ultrasonic extraction, filtering an extracting solution, and taking subsequent filtrate to obtain a medicine Terminalia fruit test solution; respectively carrying out ultra-high performance liquid chromatography detection on the reference substance solution and the medicine Terminalia fruit test solution. Chromatographic conditions of the ultra-high performance liquid chromatography comprise that a mobile phase A is acetonitrile, a mobile phase B is aphosphoric acid aqueous solution with a volume fraction of 0.1-0.3%, and an elution mode is gradient elution. The invention provides a comprehensive, effective and rapid method for controlling and evaluating the quality of the medicine terminalia fruit (collectively referred to as myrobalan).

The invention discloses application of corilagin in inhibition of coronavirus replication to play roles of anti-coronavirus drugs. The structural formula of the corilagin (Chinese name, Kelilajing; English name, Corilagin; and CAS number, 23094-69-1) is shown in the formula (I). The invention provides application of a compound as shown in the formula (I) or pharmaceutically acceptable salt thereof. The application is as follows: (a) application in preparation of a coronavirus inhibitor; and (b) application in inhibition of coronavirus. According to the invention, experiments prove that the compound shown in the formula (I) can effectively inhibit replication of SARS-CoV-2 in vitro, has good anti-SARS-CoV-2 activity, and has an important application prospect for treating SARS-CoV-2 infection.

The invention relates to a new geranium extract and a preparation method thereof, in particular to the geranium extract containing corilagin, and application of the geranium extract in medicaments for treating or preventing gastroxia and related diseases.

The invention discloses a method for preparing corilagin through a matsumura leafflower herb. The method comprises the steps of: crushing a matsumura leafflower herb medicinal material; performing Soxhlet extraction by adding 40-60 percent of ethanol; filtering an extracted solution; ultra-filtering by adding an ultra-filtration membrane system; concentrating a liquid permeating the ultra-filtration membrane system through a reverse osmosis membrane to obtain a concentrated liquid; regulating the pH value of the concentrated liquid to be pH 4-5; extracting through ethyl acetate; separating through a high-speed countercurrent chromatography after concentrating an extract liquid; collecting target components according to a chromatogram of an ultraviolet detector; and drying at a low temperature to obtain a product. By adopting the method for producing the corilagin, the energy consumption is low, the yield rate is high, and the product content is high.

The invention discloses application of Corilagin in preparation of a medicine for treating burns and scalds. The Corilagin is one of a Corilagin monomer or a Corilagin salt or a combination of the Corilagin monomer and the Corilagin salt. The Corilagin is externally used and reduces the growth of bacteria on the wound surfaces of burns and scalds by inhibiting the generation and release of inflammatory mediators to relieve the inflammatory response of the wound surfaces. Corilagin (8g/kg) reduces the inflammatory reaction of the wound surfaces by inhibiting the generation and release of inflammatory mediators, so as to reduce the growth of bacteria on the wound surfaces of the burns (scalds); and meanwhile, the protein and gene expression levels of PDGF-BB and PDGFR-beta are up-regulated, so that the expression peak is advanced, the decrustation and hair growing time of rats is shortened, and the healing rate of wound surfaces is improved. The Corilagin has an obvious treatment effect on the burns (scalds), and the curative effect of the Corilagin is even superior to that of a clinical first-line medicine 1% sulfadiazine silver.

The invention relates to a quality control method and application of P. urinaria L. capsules, and belongs to the technical field of biological medicines. Control is carried out in three aspects of raw material control, preparation method quality control and product quality control. According to the invention, modern medicine production management is integrated into quality control, the quality of medicines rely on production, and a perfect quality standard and a relatively high and reasonable method and standard for detecting the content of the active ingredient corilagin are established through whole-process quality control from the source. Pharmacological tests prove that the P. urinaria L. capsules have the effects of preventing and treating hepatic cell injury and hepatic fibrosis, and have wide application prospects.

The invention discloses a phyllanthus niruri medicinal material efficient liquid phase fingerprint establishing method and a standard fingerprint thereof. Gallic acid and Corilagin are used as comparison products, HPLC (High Performance Liquid Chromatography) detection is carried out to a comparison product solution and a test sample solution under the same chromatograph condition, gradient elution is carried out, and a chromatogram is recorded to obtain the standard fingerprint. Through the comparison of the HPLC fingerprints of 15 batches of phyllanthus niruri medicinal materials, 26 common characteristic peaks are determined, and the common characteristic peaks constitute the fingerprint characteristics of the phyllanthus niruri medicinal materials and can be used as the standard fingerprints of the phyllanthus niruri medicinal materials. The invention has the characteristics of simple method, good repeatability, a large number of characteristic peaks, good accuracy and reliability and the like, and the established standard fingerprints can effectively represent the quality of the phyllanthus niruri medicinal materials and provide theoretical and practical foundations for perfecting the quality evaluation system of the phyllanthus niruri medicinal materials.